For as much excitement as we have, trials are still early days...

For as much excitement as we have, trials are still early days which makes things non-conducive to a deal.

Most holders here think we are onto a winner and in a big way, so what would it take for BP to get your shares? I'm guessing for some it's at a bare minimum 3 billion valuation and for many much higher still.

At that kind of valuation BP would be more likely to wait for genuine extensive trial data and spend bigger money on a surer thing, than spending smaller (but not insignificant) money on dozens of unproven candidates (as you mention there's been any number of them).

Hopper always points out the big deals happen after phase II, but I think if oncarlytics in particular looks to be the real deal after phase I we could expect some interest.

I'd personally rather wait for a shot at a massive deal in a few years than entertain low ball offers at the current stage.